From the Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France (F.G., J.B., X.B., G.M.).
Department of Stroke Center, University of Versailles and Saint-Quentin-en-Yvelines, Foch Hospital, Suresnes, France (B.L., A.C.).
Stroke. 2018 Oct;49(10):2383-2390. doi: 10.1161/STROKEAHA.118.021500.
Background and Purpose- Intravenous thrombolysis (IVT) within 4.5 hours of symptom onset is currently recommended before mechanical thrombectomy (MT). We compared functional outcome, neurological recovery, reperfusion, and adverse events according to the use or not of IVT before MT. Methods- This is a post hoc analysis of the ASTER trial (Contact Aspiration Versus Stent Retriever for Successful Revascularization). The primary outcome was favorable 90-day functional outcome defined as a modified Rankin Scale of ≤2. Secondary outcomes were successful reperfusion following all procedures and after the first-line procedure, number of device passes, and change in National Institutes of Health Stroke Scale score at 24 hours. Safety outcomes included 90-day mortality and any symptomatic intracerebral hemorrhage. Results- Three hundred eighty-one patients were included, 250 of whom received IVT before MT (IVT+MT group). There were no significant differences between IVT+MT and MT-alone groups in 90-day favorable functional outcome, in successful reperfusion rate (modified Thrombolysis In Cerebral Infarction 2b or 3), in National Institutes of Health Stroke Scale score improvement at 24 hours, or in hemorrhagic complication rate. The 90-day mortality rate in the IVT+MT group was lower than after MT alone (fully-adjusted risk ratio, 0.59; 95% CI, 0.39-0.88). In a subgroup of patients without anticoagulant medication before stroke onset, we observed in the IVT+MT group a better functional outcome (fully-adjusted risk ratio, 1.38; 95% CI, 1.02-1.89), a higher successful recanalization rate after first-line strategy (fully-adjusted risk ratio, 1.26; 95% CI, 1.05-1.50), and a lower mortality rate (fully-adjusted risk ratio, 0.58; 95% CI, 0.36-0.93). Conclusions- Our results show that IVT+MT patients in the ASTER trial have lower 90-day mortality compared with those receiving MT alone. In a selected population of patients without prestroke anticoagulation, we demonstrated that IVT associated with MT might improve functional outcome and recanalization while reducing mortality rates.
背景与目的-目前建议在症状发作后 4.5 小时内进行静脉溶栓(IVT),然后再进行机械血栓切除术(MT)。我们比较了根据 MT 前是否使用 IVT 治疗的功能结局、神经恢复、再灌注和不良事件。方法-这是 ASTER 试验(接触抽吸与支架取栓治疗成功再通)的事后分析。主要结局是 90 天的良好功能结局,定义为改良 Rankin 量表≤2 分。次要结局是所有操作和一线操作后成功再灌注、器械通过次数和 24 小时时国立卫生研究院卒中量表评分的变化。安全性结局包括 90 天死亡率和任何症状性颅内出血。结果-共纳入 381 例患者,其中 250 例在 MT 前接受 IVT(IVT+MT 组)。IVT+MT 组与 MT 组在 90 天的良好功能结局、再灌注成功率(改良脑梗死溶栓 2b 或 3)、24 小时时国立卫生研究院卒中量表评分的改善或出血性并发症发生率方面无显著差异。IVT+MT 组的 90 天死亡率低于 MT 组(完全调整风险比,0.59;95%CI,0.39-0.88)。在无卒中前抗凝药物的患者亚组中,我们观察到 IVT+MT 组的功能结局更好(完全调整风险比,1.38;95%CI,1.02-1.89),一线策略后再通率更高(完全调整风险比,1.26;95%CI,1.05-1.50),死亡率更低(完全调整风险比,0.58;95%CI,0.36-0.93)。结论-我们的结果表明,与单独接受 MT 的患者相比,ASTER 试验中的 IVT+MT 患者 90 天死亡率较低。在没有卒中前抗凝的选定患者人群中,我们证明 IVT 联合 MT 可能改善功能结局和再通率,同时降低死亡率。